2 results
Approved WMORecruiting
Primary To confirm superiority on body weight reduction of CagriSema 2.4 mg/2.4 mg versus placebo as adjuncts to reduced-calorie diet andincreased physical activity in participants with overweight or obesity. Secondary To confirm superiority of…
Approved WMOCompleted
Primary objective of this randomised controlled trial is to compare transition rates to psychosis between individuals who are at UHR for developing psychosis and randomised to treatment with omega-3 fatty acids to those randomised to placebo, as…